Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson to Acquire Momenta Pharmaceuticals for $6.5 Billion in Cash

By Cory Renauer - Aug 19, 2020 at 1:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is paying a big premium to expand its autoimmune disease treatment footprint.

Johnson & Johnson (JNJ 0.24%) just took a big step into the field of immunology with a $6.5 billion deal for Momenta Pharmaceuticals (MNTA). On Tuesday, the giant healthcare conglomerate announced a definitive agreement to acquire the biotech for $52.50 per share. That works out to a whopping 70% premium over the Momenta's closing price Monday.

One of the key assets that inspired such a generous offer is nipocalimab, a potential first-in-class antibody that targets the neonatal Fc receptor, FcRn. But geography and talent were also major factors. The healthcare conglomerate is eager to expand its presence in Cambridge, Massachusetts, the world's leading hub for biopharmaceutical innovation and the location of Momenta's headquarters.

Scientist counting out cash money.

Image source: Getty Images.

Inhibiting FcRn with nipocalimab appears to reduce the concentrations of circulating immunoglobulin G antibodies thought to be responsible for damaging the nerve endings of patients with generalized myasthenia gravis and related autoimmune disorders. During a 68-patient dose-determination trial, 52% of those treated with the FcRn inhibitor reported significant symptom reductions compared to 15% of those who received a placebo.

Myasthenia gravis is one of many rare disorders driven by nerve-damaging autoantibodies -- antibodies that impede that healthy function of the body rather than attacking invaders. Nipocalimab is currently being tested in a phase 3 trial as a treatment for warm autoimmune hemolytic anemia patients, and Johnson & Johnson thinks there could many more indications in the future for autoantibody-targeting treatments. According to the company's estimate, roughly 195 million people worldwide suffer from a rare disease driven by autoantibodies.

Cory Renauer owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson and Momenta Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$170.61 (0.24%) $0.41
Momenta Pharmaceuticals, Inc. Stock Quote
Momenta Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.